Mounjaro and Antidepressants: Why They Can Be Combined and What EMA Says

You've decided to start a weight loss program with Mounjaro. But there's one question that keeps you awake at night. You're taking an antidepressant — Sertraline, Prozac, or another SSRI. Can they be combined? Will this harm your mental health?

This question is asked weekly. And it's absolutely valid. About 30% of people with excess weight take medications to support mental health. So let's figure this out together — calmly, with facts and references to official data.

Why this matters: 30% on SSRIs

Depression and excess weight often go hand in hand. This isn't just coincidence — it's a bidirectional relationship. People with depression are more likely to gain weight due to appetite changes, reduced activity, and emotional overeating. And people with excess weight are more likely to experience depression due to stigma, physical discomfort, and hormonal changes.

According to research, depression can manifest not only as low mood, but also as anxiety, insomnia, appetite changes, impulsivity, and so-called "food noise" — persistent thoughts about food [42]. That's why mental health specialists and weight management specialists often work with the same clients.

If you're taking SSRIs and want to start a weight loss program with Mounjaro, you need a clear answer. Not assumptions from forums, but data from regulators and scientists. Here's what we know.

SSRIs vs Mounjaro: No direct interactions

Let's start with the main point. Tirzepatide and SSRIs are metabolized through different pathways. This means they don't "compete" for the same liver enzymes and don't block each other's action.

Sertraline is metabolized primarily through the cytochrome P450 system, specifically the CYP2D6 enzyme [18]. And tirzepatide? It doesn't interact with these enzymes at all. In vitro data showed that tirzepatide does not inhibit or induce cytochrome P450 enzymes and does not affect renal and hepatic drug transporters [28].

Official analysis of interactions between Sertraline and tirzepatide shows: "There are no known direct drug interactions between sertraline (an SSRI) and tirzepatide (a GLP-1/GIP receptor agonist), and concurrent use is generally safe" [18]. So there are no direct contraindications.

By the way, fluoxetine (Prozac) is a potent inhibitor of CYP2D6 [30]. But since tirzepatide doesn't use this pathway, no interaction occurs. Different "roads" — different mechanisms.

EMA review 2023: Nine months of investigation

In July 2023, the European Medicines Agency (EMA) launched a large-scale study. The reason — reports of suicidal thoughts and self-harm thoughts in people taking liraglutide and semaglutide [13]. This caused a wave of concern about all GLP-1 agonists, including Mounjaro.

The investigation lasted nine months. The PRAC (Pharmacovigilance Risk Assessment Committee) requested additional data from manufacturers of all drugs in the class: Ozempic, Rybelsus, Wegovy, Victoza, Saxenda, Xultophy, Byetta, Bydureon, Lyxumia, Suliqua, and Trulicity [13].

In April 2024, EMA published its conclusions. The committee analyzed results of a large electronic medical records study that examined the frequency of suicidal thoughts in patients with excess weight and type 2 diabetes [13].

Official conclusion: evidence is insufficient to confirm an association between GLP-1 agonists and suicidal behavior. The Australian regulator TGA also confirmed: "evidence available was not sufficient to support an association between GLP-1 RAs and suicidal or self-harming behaviours" [6].

What about the FDA? The American regulator conducted its own large-scale meta-analysis. It covered 91 clinical trials with 107,910 participants: 60,338 received a GLP-1 agonist, 47,572 received placebo. Result: "no increased risk for SI/B [suicidal ideation/behavior] with GLP-1 RA use compared with placebo" [25]. Similar results were observed for other psychiatric side effects — anxiety, depression, irritability, and psychosis.

In March 2026, the FDA went even further. The agency officially asked manufacturers to remove warnings about suicidal thoughts from the labeling of Saxenda, Wegovy, and Zepbound (tirzepatide) [15]. This decision was the culmination of years of monitoring.

Mechanism 2: Rapid weight loss — psychological adaptation

Losing 10-15% of weight in a few months is not just physical transformation. It's an identity change. How do you see yourself? How do others look at you? Does your new body match your internal self-image?

Researchers note: "rapid somatic change represents more than a physical shift; it can affect the individual's internal models of self, body, and relational expectations" [3]. Rapid body change affects internal models of self, body, and relationship expectations.

In bariatric surgery, a similar pattern is observed: early mood improvements often decline over time and may return to pre-operative levels [3]. This doesn't mean weight loss is bad. It means psychological support is important.

Mechanism 3: Gut-brain axis

The last mechanism is the most scientifically intriguing. GLP-1 drugs affect the gut microbiome, vagal signaling, and neuropeptides, which can influence central nervous system function [10].

The gut-brain axis is a bidirectional connection. Changes in the microbiome can affect mood through inflammatory and metabolic pathways [21]. GLP-1 signaling intersects with neurotransmitter balance, especially serotonin pathways [2].

But there's good news here too. Chronic treatment with GLP-1 agonists increases anti-inflammatory microbial taxa (e.g., Bacteroidetes), which is associated with improvements in both mood and glycemic control [10]. Preclinical studies confirm that long-term use of GLP-1 agonists enhances hippocampal neurogenesis and reduces anxiety- and depression-like behavior [10].

From our experience, most clients don't experience significant mood changes. And those who do usually describe them as temporary — 2-4 weeks of adaptation.

Peptides that support mood

Some clients ask: is there something that can additionally support mental health during a weight loss program? Yes, there is.

Selank (AC-Selank)

This is a synthetic peptide developed to support anxiety management. It's not an antidepressant, but it can help reduce stress levels and improve adaptation. Buy Selank in Ukraine — 3,800 UAH.

Selank modulates GABAergic neurotransmission, which may help with anxiety and sleep disorders [42]. Important: this is not a replacement for SSRIs, but a possible supplement. Discuss with a specialist before starting.

Nootropics Booster (Ac-Semax)

This peptide supports cognitive functions and may have a positive effect on mood. Buy Nootropics Booster in Ukraine — 4,200 UAH.

Both peptides are available in the DOZA catalog. But we repeat: they don't replace antidepressants. If you're taking SSRIs — continue taking them as prescribed by your psychiatrist.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Mounjaro in Ukraine — DOZA catalog with all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) and official thermal delivery within 24 hours. Current Mounjaro prices 2026 — from 1,000 UAH for test dose.